Fenwick represented Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, in its additional $100 million Series B financing. The round was co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors. The funding follows the $175 million Series B funding round announced in January 2022.
Metagenomi will use the new capital to advance its lead therapeutic programs through preclinical development and into clinical proof-of-concept. More information can be obtained from the company's announcement.
The Fenwick transaction team was led by corporate partners Matthew Rossiter and Jonathan Sagot and included associates Yashreeka Huq, Joon Hwan Kim, Joanna Xu and Temitope Alagbala.